SMS PHARMACEUTICALS
|
SMS PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 10.89 | 7.80 | 5.89 | -0.83 | 7.35 |
| CEPS(Rs) | 13.66 | 11.48 | 9.54 | 4.25 | 11.82 |
| DPS(Rs) | 0.40 | 0.40 | 0.40 | 0.30 | 0.30 |
| Book NAV/Share(Rs) | 83.91 | 70.36 | 59.98 | 54.40 | 55.56 |
| Tax Rate(%) | 24.55 | 27.01 | 25.57 | 27.39 | 0.90 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.11 | 16.42 | 15.27 | 9.87 | 20.69 |
| EBIT Margin(%) | 13.96 | 13.10 | 11.73 | 4.94 | 15.83 |
| Pre Tax Margin(%) | 11.63 | 10.91 | 8.64 | 0.97 | 12.37 |
| PAT Margin (%) | 8.78 | 7.96 | 6.43 | 0.70 | 12.25 |
| Cash Profit Margin (%) | 12.76 | 12.02 | 10.55 | 6.52 | 18.06 |
| Performance Ratios | |||||
| ROA(%) | 6.87 | 6.07 | 5.10 | 0.44 | 7.97 |
| ROE(%) | 12.49 | 11.91 | 10.16 | 0.83 | 15.41 |
| ROCE(%) | 13.32 | 12.55 | 11.73 | 3.79 | 12.60 |
| Asset Turnover(x) | 0.78 | 0.76 | 0.79 | 0.63 | 0.65 |
| Sales/Fixed Asset(x) | 1.28 | 1.22 | 1.27 | 0.97 | 0.98 |
| Working Capital/Sales(x) | 3.52 | 3.68 | 3.78 | 3.55 | 3.07 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.78 | 0.82 | 0.79 | 1.04 | 1.02 |
| Receivable days | 76.30 | 94.73 | 91.77 | 65.01 | 50.80 |
| Inventory Days | 115.77 | 111.76 | 109.10 | 156.71 | 128.12 |
| Payable days | 86.69 | 112.13 | 111.30 | 97.98 | 91.63 |
| Valuation Parameters | |||||
| PER(x) | 34.41 | 27.27 | 30.25 | - | 12.76 |
| PCE(x) | 27.43 | 18.53 | 18.67 | 13.59 | 7.94 |
| Price/Book(x) | 4.47 | 3.02 | 2.97 | 1.06 | 1.69 |
| Yield(%) | 0.11 | 0.19 | 0.22 | 0.52 | 0.32 |
| EV/Net Sales(x) | 4.32 | 2.75 | 2.47 | 1.41 | 1.94 |
| EV/Core EBITDA(x) | 21.28 | 14.84 | 14.45 | 12.35 | 8.41 |
| EV/EBIT(x) | 27.35 | 19.43 | 19.52 | 26.88 | 11.49 |
| EV/CE(x) | 3.33 | 2.27 | 2.14 | 1.03 | 1.38 |
| M Cap / Sales | 3.96 | 2.41 | 2.13 | 0.94 | 1.53 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.30 | 10.36 | 35.86 | 0.42 | -7.69 |
| Core EBITDA Growth(%) | 23.89 | 19.80 | 103.90 | -50.38 | -3.83 |
| EBIT Growth(%) | 26.25 | 23.61 | 228.30 | -68.83 | -14.31 |
| PAT Growth(%) | 30.56 | 36.99 | 1,166.70 | -94.28 | 11.34 |
| EPS Growth(%) | 39.64 | 32.49 | 805.84 | -111.35 | -0.49 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.46 | 0.50 | 0.55 | 0.55 | 0.55 |
| Current Ratio(x) | 1.75 | 1.67 | 1.58 | 1.61 | 1.85 |
| Quick Ratio(x) | 0.83 | 0.84 | 0.91 | 0.73 | 0.67 |
| Interest Cover(x) | 6.00 | 5.98 | 3.80 | 1.24 | 4.57 |
| Total Debt/Mcap(x) | 0.10 | 0.16 | 0.19 | 0.52 | 0.33 |
Compare Financial Ratios of peers of SMS PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SMS PHARMACEUTICALS | ₹4,187.5 Cr | -5.2% | 12.1% | 81.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,483.0 Cr | -3.2% | -7.8% | 9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹249,248.0 Cr | 1% | 0.9% | 67.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,822.0 Cr | -1.8% | -4.8% | 32.2% | Stock Analytics | |
| CIPLA | ₹105,427.0 Cr | -3.1% | -6.5% | -12.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,492.3 Cr | -1.7% | 3.1% | -3.5% | Stock Analytics | |
SMS PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SMS PHARMACEUTICALS | -5.2% |
12.1% |
81.1% |
| SENSEX | -1.2% |
-6.4% |
-10.8% |
You may also like the below Video Courses
